Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 11/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12059736 | 0.89 | ACHE (1.00) | ACHE | |
| SCHEMBL21888375 | 0.88 | ACHE (0.78) | ACHE | |
| SCHEMBL3739573 | 0.88 | ACHE (0.78) | ACHE | |
| SCHEMBL6936357 | 0.88 | ACHE (1.00) | ACHE | |
| SCHEMBL16913320 | 0.88 | ACHE (0.77) | ACHE | |
| SCHEMBL16913352 | 0.86 | ACHE (0.76) | ACHE | |
| SCHEMBL16913351 | 0.86 | ACHE (0.76) | ACHE | |
| SCHEMBL6938768 | 0.86 | ACHE (0.76) | ACHE | |
| SCHEMBL3747171 | 0.84 | ACHE (0.71) | ACHE | |
| Piperidine SCHEMBL27588787 | 0.82 | ACHE (0.68) | ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018170410-A1 | DERIVATIVES OF SULINDAC CAN PROTECT NORMAL CELLS AGAINST OXIDATIVE DAMAGE | UNIVERSITY OF SOUTH ALABAMA (US) | 2018-09-20 | — | — | WO | disclosed |
| US-20080306271-A1 | Novel Process for Production of Highly Pure Polymorph (I) Donepezil Hydrochloride | RICHTER GEDEON NYRT. (HU) | 2008-12-11 | — | — | US | disclosed |
| US-20080306271-A1 | Novel Process for Production of Highly Pure Polymorph (I) Donepezil Hydrochloride | RICHTER GEDEON NYRT. (HU) | 2008-12-11 | — | — | US | disclosed |
| US-20070135644-A1 | PROCESS FOR MAKING DONEPEZIL | SYNTHON BV (NL) | 2007-06-14 | — | — | US | disclosed |
| US-5543298-A | ADDING SPECIFIED COMPOUND TO LIQUID SAMPLE, MEASURING RATE OF AUTOOXIDATION SPECTROPHOTOMETRICALLY | OXIS INTERNATIONAL S.A. (FR) | 1996-08-06 | — | — | US | disclosed |
| EP-0625209-B1 | METHOD FOR ASSAYING THE SOD ACTIVITY BY USING A SELF- OXIDIZABLE COMPOUND NECESSARY FOR ITS IMPLEMENTATION, SELF- OXIDIZABLE COMPOUNDS AND PREPARATION THEREOF | OXIS INT SA (FR) | 1996-07-17 | — | — | EP | disclosed |
| EP-0625209-A1 | METHOD FOR ASSAYING THE SOD ACTIVITY BY USING A SELF-OXIDIZABLE COMPOUND NECESSARY FOR ITS IMPLEMENTATION, SELF-OXIDIZABLE COMPOUNDS AND PREPARATION THEREOF. | BIOXYTECH (FR) | 1994-11-23 | — | — | EP | disclosed |
| WO-1993011258-A1 | METHOD FOR ASSAYING THE SOD ACTIVITY BY USING A SELF-OXIDIZABLE COMPOUND NECESSARY FOR ITS IMPLEMENTATION, SELF-OXIDIZABLE COMPOUNDS AND PREPARATION THEREOF | BIOXYTECH (FR) | 1993-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306271-A1 | Novel Process for Production of Highly Pure Polymorph (I) Donepezil Hydrochloride | DRD4, IDO1, ADH1A | ACHE 71/4885 |
| US-20070135644-A1 | PROCESS FOR MAKING DONEPEZIL | MAOA, ACHE, CHAT | ACHE 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.